Testosterone Therapy and a GLP-1 at the Same Time

The short version

This is the male mirror of a question this desk has already answered for women in taking a GLP-1 and hormone therapy at the same time: two hormonal interventions, running at once, with almost nothing published about the pair.

The honest headline comes in two parts, and the second is more useful than the first.

No randomized trial has evaluated the combination. A 2026 review that set out to assess exactly this reports that no randomized trials have directly examined the combined effects of GLP-1 receptor agonists and testosterone replacement on body composition, and states that the available evidence does not support routine combined therapy¹. That is a firmer conclusion than the usual call for more research.

And the combination may be a question that dissolves. A separate 2026 study found that incretin therapy on its own raised testosterone substantially — enough that its authors suggest these drugs could reduce the need for exogenous testosterone altogether².

Why anyone proposes the combination

The reasoning is not silly, which is why it needs answering properly.

Weight lost on a GLP-1 is not purely fat. Some fat-free mass goes with it — the same phenomenon covered for the reader herself on muscle loss on a GLP-1 and bone density and lean mass. Testosterone, meanwhile, is a well-established regulator of skeletal muscle, and replacing it in men who are deficient reliably increases lean body mass.

Now add the fact that obesity itself lowers testosterone. That creates a group of men who are simultaneously losing weight quickly and carrying what the review calls a diminished anabolic reserve — and the proposal follows naturally: give them testosterone alongside the GLP-1 to protect the muscle.

The review examines that chain and finds the interaction biologically plausible. It also finds nobody has tested it. Its recommendation is unchanged from ordinary practice: testosterone replacement is appropriate for men who meet the existing guideline criteria for low testosterone, and assessing androgen status is reasonable in men undergoing substantial weight loss. It is not endorsed as a muscle-protection add-on¹.

The finding that reframes the question

A retrospective study published in 2026 looked at men treated with incretin-based drugs and measured what happened to their testosterone². Two hundred and fifteen men had total testosterone measured before and during therapy; 61 had paired free testosterone. Mean age 55, mean body mass index 36.3, and 77% had type 2 diabetes.

Two things make this worth reading carefully.

The first is how modest the weight loss was. About 5% — far less than a GLP-1 taken to a full dose usually produces — and the testosterone gains still cleared statistical significance, with the largest gains in the men who lost the most.

The second is a limitation that has to be stated, because it is the difference between this page being honest and being wrong: men receiving androgen-related therapies were excluded from that study. It is not a study of the combination. It describes what happens on the GLP-1 alone. What it supports is the authors' own conclusion — that incretins may reverse obesity-related low testosterone and potentially reduce the need for exogenous testosterone — and not any claim about taking both.

The practical form of that is a question worth asking out loud: has his testosterone been re-measured after meaningful weight loss? If the deficiency was driven by the weight, the number that justified starting testosterone may no longer describe him.

The reason it matters which one he is on

If conception is anywhere in the plan, this stops being a body-composition question.

A 2026 systematic review pooling ten studies and 639 men found that luteinizing hormone and follicle-stimulating hormone — the two brain signals that drive sperm production — were preserved or increased on GLP-1 receptor agonists, in direct contrast to the suppression seen in the testosterone-therapy comparison groups³. The reviewers describe GLP-1s as potentially fertility-sparing alternatives to testosterone in some cases of obesity-related low testosterone. They also found semen improvements only in men who were obese or hypogonadal, and no significant changes in healthy men.

A randomized trial makes the same point in one set of men: semaglutide against intramuscular testosterone undecanoate over 24 weeks, and the testosterone arm's sperm concentration and total sperm number fell significantly while the semaglutide arm's did not⁴.

Suppressing sperm production is not a side effect of testosterone therapy; it is how it works. Taking both does not cancel that out.

What a tirzepatide pilot adds

A controlled pilot study enrolled 83 men with obesity and metabolic hypogonadism, put everyone on a reduced-calorie diet and daily walking, then split them between tirzepatide, no drug, and transdermal testosterone, with hormone panels at two months⁵. Its authors position tirzepatide as promising specifically for hypogonadism arising from metabolic causes — which is a statement about a population, not a general recommendation, and certainly not a combination result.

What to actually do with this

The decision belongs to whoever prescribes, and it should be one prescriber who knows about both. Two clinicians each managing one drug is the arrangement in which this falls through.

Ask whether the testosterone level has been rechecked since the weight came off. That single question is the most actionable thing on this page.

Say it out loud if conception is in the plan. It changes the calculation more than anything else here.

Do not add testosterone to protect muscle. The review that examined that idea declined to endorse it, and resistance training and adequate protein have the evidence that the combination does not.

Where this sits on the evidence scale

GLP-1 and testosterone replacement taken together: no direct evidence. No randomized trial has evaluated the combination on body composition, and the review that searched for one says the available evidence does not support routine combined therapy.

GLP-1s raise total testosterone in men with obesity: moderate. Consistent across a retrospective cohort of 215 men and a systematic review of ten studies, though free testosterone moves less reliably because binding protein rises alongside it.

GLP-1s preserve the gonadotropin signal while testosterone therapy suppresses it: strong, and long-established andrology rather than a new finding.

Testosterone as a lean-mass strategy during GLP-1 weight loss: untested. Plausible mechanism, zero trial data, and the review calls for prospective studies with standardized body-composition measures before anyone acts on it.